CeriBell (CBLL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.49
- Estimate
- -$0.52
- Surprise
- +5.6%
- Revenue (period 2026-09-30)
- $29.3M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
CeriBell (CBLL) reported a narrower loss than forecast — adjusted EPS of -$0.49 against the -$0.52 estimate (a 5.6% beat on a still-unprofitable quarter).
Coverage in the report window
- CeriBell Q3 2026 Earnings Call Transcript — benzinga, 2026-11-03
- CeriBell, Inc. Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-03
- CeriBell Raises FY2026 Sales Guidance from $114.000M-$117.000M to $115.000M-$117.000M vs $115.537M Est — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates CBLL Sell at 5.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +5.6% surprise compares with a +8.4% four-quarter average.
What argues against it
- Concentration risk — Product: Ceribell System
- Concentration risk — Geographic: United States sales (100.0%)
- Target reached (-9.0% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.27
- Stop
- $26.29
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
CBLL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.08B
- P/E (fwd)
- -17.4
- 52-week range
- $10.85–$28.89
- Off 52-week high
- 2.1%
- RSI (14)
- 58
- Volume vs avg
- 1.18×
- Score today
- 5.6/10